PCK2 and renal cell carcinoma: As shown in Figure 4H-I, the drug sensitivity curve obtained in the CCK8 assay revealed a faster rate of decline in the PCK2 overexpression group, regardless if it is in resistant RCC cells or normal RCC cells.